Selected for Two Preclinical Presentations at AACR 2026
Efficacy Demonstrated in Pancreatic Cancer Regardless of BRCA Mutation Status

Onconic Therapeutics' anticancer drug candidate 'Nesuparib' will have two sets of preclinical study results on small cell lung cancer and pancreatic cancer presented at an international conference.

Main page of the AACR Annual Meeting 2026 website. Website screenshot

Main page of the AACR Annual Meeting 2026 website. Website screenshot

View original image

On March 18, Onconic Therapeutics announced that two studies related to Nesuparib have been selected for poster presentations at the American Association for Cancer Research (AACR) 2026, which will take place next month in San Diego, USA. The study abstracts have been released through the conference.


In cell experiments for small cell lung cancer, Nesuparib demonstrated up to 133 times greater cancer cell growth inhibition compared to the existing PARP inhibitor olaparib, and approximately 25 times greater than irinotecan. In animal models, it recorded a tumor inhibition rate of 66.5%, surpassing olaparib (36%) and irinotecan (42.9%).


In the pancreatic cancer preclinical study, antitumor effects were observed regardless of BRCA mutation status. In cell experiments, when combined with standard treatments (gemcitabine and nab-paclitaxel), cancer cell viability decreased by more than 70%. In animal models, combination therapy reduced tumor size by 79%, showing a stronger inhibitory effect compared to monotherapy (31%).



Nesuparib is based on a dual mechanism that inhibits both PARP and tankyrase simultaneously. The company plans to continue the ongoing phase 2 clinical development for pancreatic cancer based on these results.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing